Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma

Authors:
  • OBOlivier Bouché
    Olivier Bouché
  • OROlivier Romano
    Olivier Romano
  • ESElodie Scaglia
    Elodie Scaglia
  • SCStéphane Cattan
    Stéphane Cattan
  • AHAlexandra Heurgue
    Alexandra Heurgue
  • SLStéphanie Lagarde
    Stéphanie Lagarde
  • CMChristophe Mariette
    Christophe Mariette
  • JTJean-Pierre Triboulet
    Jean-Pierre Triboulet
  • FPFrançois-René Pruvot
    François-René Pruvot
  • MHMohamed Hebbar
    Mohamed Hebbar

Abstract
Backgrounds: The combination gemcitabine-oxaliplatin (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC. Methods: All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study: gemcitabine 1,000 mg/m2 on day 1, and oxaliplatin 100 mg/m2 on day 2, treatment repeated every 2 weeks until progression or unacceptable toxicity. Results: Forty-four patients were enrolled. Efficacy: 1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months. Toxicity: grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients. Conclusion: The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard gemcitabine-cisplatin combination.